BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9087486)

  • 41. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
    Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
    Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.
    Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 May; 41(5):1037-41. PubMed ID: 9145865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
    Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore.
    Kuah BG; Kumarasinghe G; Doran J; Chang HR
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2502-3. PubMed ID: 7840598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Larivière LA
    Antimicrob Agents Chemother; 1991 May; 35(5):813-8. PubMed ID: 1854162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Jan; 41(1):148-55. PubMed ID: 8980771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations.
    Lecso-Bornet M; Bergogne-Bérézin E
    J Antimicrob Chemother; 1997 Nov; 40(5):717-20. PubMed ID: 9421322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.
    Hejnar P; Kolár M; Chmela Z
    Folia Microbiol (Praha); 2004; 49(1):71-4. PubMed ID: 15114869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
    Pelak BA; Woods GL; Teppler H; Friedland I; Bartizal K; Motyl M
    J Chemother; 2002 Jun; 14(3):227-33. PubMed ID: 12120874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility of the anaerobic gram-negative non-sporulating rod, Bilophila wadsworthia to beta-lactams, beta-lactamase inhibitors, meropenem, metronidazole, clindamycin and quinolones.
    Schumacher UK; Single B
    Zentralbl Bakteriol; 1998 May; 287(4):421-5. PubMed ID: 9638871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.